

A REVIEW ON DRUG DELIVERY SYSTEMS FOR TREATING THE OCULAR DRY EYE SYNDROME

¹GadiyapdiManikanta,²Padigappagari Sureshreddy,³Andra ASE Pravallika ,⁴Goriparthi Ramyasri,
⁵M.Mohan varma.

¹ Department of Pharmaceutics, Shri Vishnu College Of Pharmacy, Bhimavaram,India.

ABSTRACT: The common tear film disease known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS) is brought on by decreased tear production or increased evaporation and presents with a wide range of signs and symptoms. The prevalence, definition, causes, diagnostic procedures, and medical management of dry eye disease are all covered in detail in the current study based on interpretation of the literature. The physiological integrity of the ocular surface is maintained by a number of systems, and when one of these systems is disrupted, symptoms may or may not appear. Therefore, it's important to make a precise diagnosis of dry eyes when there is little to no impairment of physiological function. Additionally, the research examines several colloidal drug delivery technologies and present difficulties in creating topical ophthalmic drug delivery systems to treat KCS. In order to produce ocular delivery systems with high treatment efficacy, newer, more sensitive diagnostic procedures and innovative therapeutic agents have been developed. This is due to the widespread occurrence and number of components involved. The purpose of this review is to raise knowledge of the diagnosis and treatment of KCS, as well as recent advancements and upcoming difficulties in the management of dry eye disease, among patients, healthcare providers, and researchers.

key words: keratoconjunctivitis sicca,dry eye syndrome.

INTRODUCTION

Dry eye disease, also known as keratoconjunctivitis sicca, is a condition in which the eyes do not produce enough tears, or the tears evaporate too quickly. This can lead to discomfort, pain, and difficulty seeing. Ocular drug delivery systems refer to methods for delivering medications to the eye for the treatment of various conditions such as glaucoma, dry eye, and infections. There are several different types of ocular drug delivery systems, including: Eye drops, these are the most common form of ocular drug delivery, and are typically easy to administer at home. However, they have a relatively low bioavailability, meaning that only a small amount of the medication actually reaches the eye. Ointments are applied to the eye like eye drops, but they are thicker and tend to have a longer duration of action. However, they can cause blurry vision and are more difficult to apply than eye drops. Implantable devices are small devices that are surgically implanted in the eye and release the medication over a period of time. Implantable devices can provide sustained drug delivery, but they require a surgical procedure to insert and remove them. Transscleral drug delivery involves administering the medication through the sclera (the white part of the eye) using a needle or a transscleral iontophoretic device. This method can provide sustained drug delivery, but it requires specialized equipment and trained personnel to administer. There are also other experimental ocular drug delivery methods being developed, such as nanoparticle-based delivery systems and thermal-sensitive hydrogels. These methods are still in the early stages of development and are not yet widely available.

SYMPTOMS

The main symptoms of dry eye disease include:

- Eye dryness
- Itching
- Burning
- Redness
- Discharge
- Sensitivity to light
- Difficulty wearing contact lenses
- Stringy mucus in or around the eyes
- There are several factors that can contribute to dry eye disease, including:
 - Age (older people are more prone to dry eye)
 - Gender (women are more prone to dry eye than men)
 - Certain medications (such as antihistamines, decongestants, and antidepressants)
 - Environmental factors (such as dry air, wind, and smoke)
 - Health conditions (such as rheumatoid arthritis, Sjögren's syndrome, and thyroid problems)

Treatment for dry eye disease may include the use of artificial tears, warm compresses, lid hygiene, and other eye drops. In severe cases, a person with dry eye disease may need to undergo a procedure called punctal occlusion, in which the tear ducts are partially or completely blocked to help retain moisture in the eyes.

Dry eye is a condition in which the eyes do not produce enough tears or the tears produced are of poor quality. This can lead to discomfort, vision problems, and an increased risk of eye infections. Dry eye can be caused by a variety of factors, including age, certain medications, and underlying medical conditions.

Treatment for dry eye may involve a combination of lifestyle changes, artificial tears, and medications. Lifestyle changes may include increasing humidity in the home or workplace, avoiding situations that exacerbate dry eye (such as smoking or staring at screens for long periods of time), and using a humidifier. Artificial tears, which are available over the counter or by prescription, can help to lubricate the eyes and provide relief from dryness.

Medications that may be used to treat dry eye include eye drops or ointments that contain ingredients such as cyclosporine (Restasis) or lifitegrast (Xiidra). These medications help to increase tear production and improve the quality of the tears. In severe cases of dry eye, a procedure called punctal occlusion may be performed. This involves closing the tear ducts, which helps to retain tears on the surface of the eye.

TREATMENT METHODS

There are several drug delivery systems that are used in the treatment of dry eye. These include:

Eye drops: These are the most common form of treatment for dry eye. They can be used to deliver a variety of medications, including artificial tears, lubricants, and anti-inflammatory drugs.

Ointments: These are thicker and longer-lasting than eye drops, and are typically used at bedtime to provide extended relief throughout the night.

Gels: These are similar to ointments, but are less thick and greasy. They can be used during the day to provide extended relief from dry eye symptoms.

Implants: These are small, biodegradable devices that are placed in the lower eyelid and release medication over a period of time. They can be used to deliver a variety of medications, including anti-inflammatory drugs and lubricants.

Lipid-based drug delivery systems: These are designed to mimic the natural lipid layer of the tear film and help to stabilize the tear film. They can be used to deliver a variety of medications, including anti-inflammatory drugs and lubricants.

Punctal plugs: These are small devices that are inserted into the puncta (small openings in the corners of the eyelids) to help retain tears on the surface of the eye. They can be used to deliver a variety of medications, including lubricants and anti-inflammatory drugs.

It's important to note that the most appropriate drug delivery system will depend on the specific needs and preferences of the individual patient, as well as the severity of their dry eye symptoms.

EYE DROPS

There are several types of eye drops that can be used to treat dry eye, including artificial tears, lubricating eye drops, and anti-inflammatory eye drops.

Artificial tears are the most common type of eye drop used to treat dry eye. These eye drops contain a sterile, water-based solution that is similar to natural tears. They can be used to relieve dryness, itching, and burning caused by dry eye. Artificial tears are available over the counter and do not require a prescription.

Lubricating eye drops, also known as "gel tears," are thicker than artificial tears and are used to provide long-lasting relief from dry eye. They may be recommended for people with severe dry eye or for those who experience dryness during the night.

Anti-inflammatory eye drops, such as corticosteroids, can be used to reduce inflammation in the eyes. These eye drops are usually prescribed for short-term use to treat severe dry eye or to help control flare-ups of the condition.

It is important to follow the instructions provided by your doctor or the package insert when using eye drops. Some eye drops may need to be used more frequently or at specific times of day. It is also important to properly store eye drops, as contamination can occur if the dropper tip comes into contact with any surface.

OINTMENTS

Ointments are one treatment option that can be used to help relieve the symptoms of dry eye disease. Ointments are thicker and more viscous than other types of eye drops, and they tend to stay in the eye longer, providing longer-lasting relief. They are typically used at bedtime, as they can cause vision to be blurry for a short period of time after use. Some common ointments used to treat dry eye disease include mineral oil, petrolatum, and paraffin.

GELS

Gels are a type of eye drop that are used to treat dry eye syndrome, a condition in which the eyes do not produce enough tears or produce tears that are of low quality. Dry eye syndrome can cause symptoms such as redness, itching, burning, and a feeling of grittiness in the eyes.

There are several different types of gels that can be used to treat dry eye syndrome, including:

Artificial tear gels: These gels contain a combination of lubricants and other ingredients that mimic the composition of natural tears. They are used to lubricate and moisten the eyes, and can be used as needed to relieve dry eye symptoms.

Lipid-based gels: These gels contain fatty acids and other lipids that help to stabilize the tear film and prevent tears from evaporating too quickly. They may be used in conjunction with artificial tear gels to provide additional lubrication.

Mucolytic gels: These gels contain agents that help to break down mucus and other debris that can accumulate in the eyes, which can contribute to dry eye symptoms.

Anti-inflammatory gels: These gels contain ingredients that help to reduce inflammation in the eyes, which can be helpful in managing dry eye syndrome.

Implantable devices for the treatment of dry eye are a type of medical device that is inserted into the eye to help improve tear production and reduce the symptoms of dry eye. These devices are typically small and are placed in the lower eyelid, near the tear duct.

There are several types of implantable devices that are used in the treatment of dry eye, including:

PUNCTAL PLUGS: These are small plugs that are inserted into the puncta, which are the small openings in the corner of the eye that allow tears to drain into the tear duct. Punctal plugs help to retain the natural tears on the surface of the eye, which can help to improve tear film stability and reduce the symptoms of dry eye.

INTRACANALICULAR PLUGS: These are similar to punctal plugs, but they are inserted deeper into the tear duct itself. Intracanalicular plugs are designed to block the tear duct and help to keep tears on the surface of the eye for longer periods of time.

LACRISERT: This is a small, dissolvable pellet that is inserted into the lower eyelid. Lacrisert releases a lubricating substance that helps to improve tear film stability and reduce the symptoms of dry eye.

PUNCTAL OCCLUSION: This is a procedure in which the puncta are sealed or closed off, either permanently or temporarily, in order to keep tears on the surface of the eye. Punctal occlusion can be performed surgically or using a laser.

PUNCTAL PLUGS

Punctal plugs are small, usually silicone or collagen, devices that are inserted into the puncta, which are the small openings in the inner corners of the eyelids that allow tears to drain into the nasal cavity. They are used to treat dry eye syndrome, which is a condition in which the eyes do not produce enough tears or the tears evaporate too quickly, leading to dryness, discomfort, and possibly vision problems.

There are two main types of punctal plugs: temporary and permanent. Temporary plugs are made of dissolvable materials and are used to see if plugging the puncta helps with dry eye symptoms. Permanent plugs are made of silicone or other materials and are meant to be a long-term solution. Punctal plugs can be inserted in a simple in-office procedure. The eye is numbed with drops and the plug is inserted using forceps or a special inserter. The procedure is usually well tolerated and does not require any downtime. Punctal plugs can be removed or adjusted if necessary. They may need to be removed if the plugs cause discomfort or if the dry eye symptoms do not improve. In some cases, the size or number of punctal plugs may need to be adjusted to optimize their effectiveness. Punctal plugs are just one option for treating dry eye syndrome.

NANOPARTICLES

Some research has suggested that nanoparticles may be useful in the treatment of dry eye.

One possible use of nanoparticles in the treatment of dry eye is to deliver drugs directly to the eye. For example, nanoparticles containing anti-inflammatory drugs or lubricants could be used to treat dry eye caused by inflammation or a lack of natural lubrication.

Another potential use of nanoparticles in the treatment of dry eye is to enhance the stability and effectiveness of tears. For example, nanoparticles could be used to stabilize the lipid layer of the tear film, which helps to prevent tears from evaporating too quickly. It is important to note that research on the use of nanoparticles in the treatment of dry eye is still in the early stages, and more research is needed to fully understand the potential benefits and risks of this approach.

REFERENCES

1. M. A. Lemp, C. Baudouin, J. Baum et al., "The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international Dry Eye WorkShop," *Ocular Surface*, vol. 5, no. 2, pp. 75–92, 2007.
2. N. Delaleu, R. Jonsson, and M. M. Koller, "Sjögren's syndrome," *European Journal of Oral Sciences*, vol. 113, no. 2, pp. 101–113, 2005.
3. "Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the international dry eye workshop (2007)," *The Ocular Surface*, vol. 5, no. 2, pp. 108–152, 2007.
4. M. Uchino, Y. Uchino, M. Dogru et al., "Dry eye disease and work productivity loss in visual display users: the Osaka study," *The American Journal of Ophthalmology*, vol. 157, no. 2, pp. 294–300, 2014.
5. J. R. Grubbs Jr., S. Tolleson-Rinehart, K. Huynh, and R. M. Davis, "A review of quality of life measures in dry eye questionnaires," *Cornea*, vol. 33, no. 2, pp. 215–218, 2014.
6. J. A. Paulsen, K. J. Cruickshanks, M. E. Fischer et al., "Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life," *American Journal of Ophthalmology*, vol. 157, no. 4, pp. 799–806, 2014.
7. B. Miljanović, R. Dana, D. A. Sullivan, and D. A. Schaumberg, "Impact of dry eye syndrome on vision-related quality of life," *American Journal of Ophthalmology*, vol. 143, no. 3, pp. 409.e2–415.e2, 2007.
8. L. Tong, S. Waduthantri, T. Y. Wong et al., "Impact of symptomatic dry eye on vision-related daily activities: the Singapore Malay eye study," *Eye*, vol. 24, no. 9, pp. 1486–1491, 2010.
9. D. A. Schaumberg, R. Dana, J. E. Buring, and D. A. Sullivan, "Prevalence of dry eye disease among US men: estimates from the physicians' health studies," *Archives of Ophthalmology*, vol. 127, no. 6, pp. 763–768, 2009.
10. A. Sharma and H. B. Hindman, "Aging: a predisposition to dry eyes," *Journal of Ophthalmology*, vol. 2014, Article ID 781683, 8 pages, 2014.
11. S. E. Moss, R. Klein, and B. E. Klein, "Prevalence of and risk factors for dry eye syndrome," *Archives of Ophthalmology*, vol. 118, no. 9, pp. 1264–1268, 2000.
12. S. C. Pflugfelder, "Prevalence, burden, and pharmacoeconomics of dry eye disease," *The American Journal of Managed Care*, vol. 14, no. 3, supplement, pp. S102–S106, 2008.
13. O. D. Schein, B. Munuz, J. M. Tielsch, K. Bandeen-Roche, and S. West, "Prevalence of dry eye among the elderly," *The American Journal of Ophthalmology*, vol. 124, no. 6, pp. 723–728, 1997.
14. J. A. Smith, J. Albenz, C. Begley et al., "The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international Dry Eye WorkShop (2007)," *Ocular Surface*, vol. 5, no. 2, pp. 93–107, 2007.

15. M. A. Lemp, "Advances in understanding and managing dry eye disease," *The American Journal of Ophthalmology*, vol. 146, no. 3, pp. 350.e1–356.e1, 2008.
16. D. A. Schaumberg, D. A. Sullivan, and M. R. Dana, "Epidemiology of dry eye syndrome," *Advances in Experimental Medicine and Biology*, vol. 506, pp. 989–998, 2002.
17. D. A. Schaumberg, J. E. Buring, D. A. Sullivan, and M. Reza Dana, "Hormone replacement therapy and dry eye syndrome," *The Journal of the American Medical Association*, vol. 286, no. 17, pp. 2114–2119, 2001.
18. S. S. Kassin and H. M. Moutsopoulos, "Clinical manifestations and early diagnosis of Sjögren syndrome," *Archives of Internal Medicine*, vol. 164, no. 12, pp. 1275–1284, 2004.
19. M. Fujita, T. Igarashi, T. Kurai, M. Sakane, S. Yoshino, and H. Takahashi, "Correlation between dry eye and rheumatoid arthritis activity," *The American Journal of Ophthalmology*, vol. 140, no. 5, pp. 808–813, 2005.
20. S. C. Sacca, A. Poscotto, G. M. Venturino et al., "Prevalence and treatment of *Helicobacter pylori* in patients with blepharitis," *Investigative Ophthalmology & Visual Science*, vol. 47, pp. 501–508, 2006.
21. C. Blehm, S. Vishnu, A. Khattak, S. Mitra, and R. W. Yee, "Computer vision syndrome: a review," *Survey of Ophthalmology*, vol. 50, no. 3, pp. 253–262, 2005.
22. J. C. Lang and R. E. Roehrs, "Ophthalmic preparations," in *Remington: The Science and Practice of Pharmacy*, D. B. Troy, Ed., vol. 1, pp. 850–854, Lippincott Williams Wilkins, Philadelphia, Pa, USA, 21st edition, 2005.
23. J. Lakshmi Prabha, "Tear secretion—a short review," *Journal of Pharmaceutical Sciences and Research*, vol. 6, no. 3, pp. 155–157, 2014.
24. E. Peters and K. Colby, "The tear film," in *Foundation Volume 2: Physiology of the Eye and Visual System*, W. Tasman and E. A. Jaeger, Eds., Duane's Foundations of Clinical Ophthalmology, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 2006, Duane's Ophthalmology on CD rom.
25. M. A. Lemp, "Report of the national eye institute/industry workshop on clinical trials in dry eyes," *CLAO Journal*, vol. 21, no. 4, pp. 221–232, 1995.

